Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

COPD Clinical Trial

Official title:

Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06040424
• Other study ID #: NEU-01.22
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 28, 2023
• Est. completion date: June 2024

Study information

• Verified date: October 2023
• Source: Neutec Ar-Ge San ve Tic A.S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable moderate-severe-very severe COPD patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 74
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients aged 40 years and older who have been newly diagnosed or followed up with a diagnosis of COPD.
• Stable moderate-severe-very severe COPD patients with a post-bronchodilator FEV1/FVC ratio <70% and a postbronchodilator FEV1 value <80% at the screening visit will be included in the study.
• Symptom status such as chronic cough, sputum production, and progressive dyspnea with the BCSS (Breathlessness, Cough and Sputum Scale) Index will be evaluated, and the COPD staging of the patient with CAT (COPD Assessment Test) and the severity of dyspnea with mMRC (Modified Medical Research Council) will be determined.
• Patients with at least 10 pack/year smoking status or smoking history (patients who have quit smoking for at least 6 months or more are defined as ex-smokers).
• Patients who have not experienced an exacerbation in the previous 4 weeks.
• If the study participant is female; women using appropriate contraception (pregnancy test will be performed at screening visit).
• Patients with the ability to communicate with the investigator.
• Patients who accept to comply with the protocol.
• Patients who sign written informed consent form.

Exclusion Criteria:

• History of hypersensitivity to anticholinergics or SABAs (short acting beta agonist).
• History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 3 days prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
• Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit.
• SGOT (serum glutamic-oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic-pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL.
• History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
• Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
• Recent (within =3 months prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment.
• Regularly use of daytime CPAP (continuous positive airway pressure) oxygen therapy for longer than 1 hour per day.
• Initiation of pulmonary rehabilitation within the 3 months prior the screening visit.
• History of lung volume reduction surgery
• Drug or alcohol abuse
• Presence of active tuberculosis
• History of atopy or allergic rhinitis
• Presence of active cancer
• Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
• Pregnancy or lactation
• Presence of known symptomatic prostatic hypertrophy requiring treatment
• Presence of known narrow-angle glaucoma requiring treatment
• Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.

Related Conditions & MeSH terms

• COPD
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Combination Product:
• Ipratropium / Levosalbutamol Fixed Dose Combination
New combination test treatment

Drug:
• Ipratropium + Levosalbutamol Free Dose Combination
Free combination control treatment

Locations

Country	Name	City	State
Turkey	Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Neutec Ar-Ge San ve Tic A.S

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)	Change From Baseline in Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-8h.	8 hours
Secondary	FEV1 area under the curve from 0-3 h (FEV1 AUC 0-3 h)	Change From Baseline in FEV1 AUC (0-3h).	3 hours
Secondary	FEV1 AUC 3-6 h	Change From Baseline in FEV1 AUC (3-6h).	3 to 6 hours
Secondary	FEV1 AUC 6-8 h	Change From Baseline in FEV1 AUC (6-8h).	6 to 8 hours
Secondary	FVC AUC 0-3 h	Change From Baseline in FVC AUC (0-3h).	3 hours
Secondary	FVC AUC 3-6 h	Change From Baseline in FVC AUC (3-6h).	3 to 6 hours
Secondary	FVC AUC 6-8 h	Change From Baseline in FVC AUC (6-8h).	6 to 8 hours
Secondary	FVC AUC 0-8 h	Change From Baseline in FVC AUC (0-8h).	0 to 8 hours
Secondary	Change From Baseline in FEV1 and FVC within the first 30 minutes after dosing (mL)	Spirometric measurements will be performed pre-treatment and 5 min, 30 min and 1 h, 3 h, 6h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated.	Baseline, 30 minutes post-dose at treatment day
Secondary	Mean Maximum Change From Baseline in FEV1 and FVC within the first 1 hours after dosing (mL)	Spirometric measurements will be performed pre-treatment and 5 min, 30 min and 1 h, 3 h, 6h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated.	Baseline, 1 hours post-dose at treatment day
Secondary	Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours (mL)	Spirometric measurements will be performed pre-treatment and 5 min, 30 min and 1 h, 3 h, 6h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated.	Baseline, 0 to 8 hours post-dose at treatment day
Secondary	The Time to Onset of Bronchodilator Response	Bronchodilator response is defined as 100 mL improvement in FEV1.	Baseline, 0 to 8 hours post-dose at treatment day
Secondary	Evaluation of Safety	Number of participants with Adverse Events, with abnormal physical examinations, abnormal laboratory test results and abnormal ECGs.	Baseline, 0 to 24 hours post-dose